ArticleTranslational vision science & technology2026
Histatin-5 Improves In Vivo Corneal Wound Healing and Immunohistochemical Neovascular Markers After Acute Alkali Injury.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: Histatin-5 (Hst5), an endogenous antimicrobial peptide, has recently been shown to promote corneal epithelial wound healing and reduce inflammation after injury. This study aimed to investigate whether topical Hst5 treatment can inhibit corneal neovascularization and promote tissue recovery in a murine model of alkali burn injury. Methods: Mice were randomly assigned to two groups: balanced salt solution (BSS) and Hst5-treated (5 mL of 20 µM stock) after alkali injury. Alkali burns were induced on the cornea of each mouse and topically treated three times a day for up to two weeks. Wound closure was analyzed through epithelial wound healing, corneal opacity, and neovascularization. Histologic analysis was also conducted. Results: Topical Hst5 treatment significantly accelerated corneal wound healing, reducing residual epithelial defect area by ∼60% at 18 hours and achieving complete closure by 24 hours, compared with BSS-treated controls. Corneal opacity scores were significantly lower in the Hst5 group from Day 7 with near-clear corneas by Day 14. Neovascularization scores were markedly reduced in Hst5-treated eyes at Day 14, and accompanied by decreased infiltration of CD45⁺ immune cells. Conclusions: Hst5 reduces alkali burn-induced corneal epithelial wound healing time, opacification and neovascularization in murine models. Future research is required before clinical implementation; however, the results suggest a potential therapeutic role for Hst5 for alleviating the adverse effects associated with acute corneal alkali injuries. Translational Relevance: Topical Histatin-5 promotes epithelial regeneration and suppresses inflammation-driven corneal neovascularization following alkali injury, suggesting Hst5 as a novel, biologically-derived treatment to accelerate corneal healing and prevent vision loss after chemical burns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.